Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CSBR

Champions Oncology (CSBR) Stock Price, News & Analysis

Champions Oncology logo

About Champions Oncology Stock (NASDAQ:CSBR)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$9.00
$9.72
50-Day Range
$9.11
$10.96
52-Week Range
$3.60
$11.99
Volume
32,633 shs
Average Volume
36,551 shs
Market Capitalization
$114.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Buy

Company Overview

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Remove Ads

Champions Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

CSBR MarketRank™: 

Champions Oncology scored higher than 72% of companies evaluated by MarketBeat, and ranked 254th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Champions Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Champions Oncology has only been the subject of 1 research reports in the past 90 days.

  • Read more about Champions Oncology's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Champions Oncology is -144.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Champions Oncology is -144.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    2.03% of the float of Champions Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Champions Oncology has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Champions Oncology has recently increased by 7.09%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Champions Oncology does not currently pay a dividend.

  • Dividend Growth

    Champions Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.03% of the float of Champions Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Champions Oncology has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Champions Oncology has recently increased by 7.09%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Champions Oncology this week, compared to 6 articles on an average week.
  • Search Interest

    Only 2 people have searched for CSBR on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Champions Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    46.98% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Champions Oncology's insider trading history.
Receive CSBR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter.

CSBR Stock News Headlines

Trump… a socialist?
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Champions Oncology price target raised to $12 from $8 at Craig-Hallum
See More Headlines

CSBR Stock Analysis - Frequently Asked Questions

Champions Oncology, Inc. (NASDAQ:CSBR) announced its earnings results on Tuesday, March, 11th. The biotechnology company reported $0.31 earnings per share for the quarter. The biotechnology company earned $17.04 million during the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Champions Oncology investors own include Intel (INTC), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Advanced Micro Devices (AMD) and Bristol-Myers Squibb (BMY).

Company Calendar

Last Earnings
3/11/2025
Today
4/03/2025
Fiscal Year End
4/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CSBR
Employees
143
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+45.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,280,000.00
Pretax Margin
-1.19%

Debt

Sales & Book Value

Annual Sales
$50.15 million
Price / Cash Flow
N/A
Book Value
($0.14) per share
Price / Book
-58.76

Miscellaneous

Free Float
7,327,000
Market Cap
$113.68 million
Optionable
Optionable
Beta
0.28

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:CSBR) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners